ConductScience.org, home

Comparison · NCT01985321-sae

Merlin - Ethanol/Glycolic Acid Solution vs Ethanol: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Merlin - Ethanol/Glycolic Acid Solution vs Ethanol: serious adverse events. Trial comparisons, record NCT01985321-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01985321-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.0409wilson
Risk in group 200.000000000000000003470.0442wilson
Risk difference, group 1 minus group 20-0.04420.0409newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Merlin - Ethanol/Glycolic Acid Solution36 applications over a 96 hour period~ethanol/glycolic acid solution: ethanol/glycolic acid solution090EG000
Group 2Ethanol36 applications over a 96 hour period083EG001

Harm

What it counts
Total, serious adverse events
Time frame
All subjects were followed daily until their cold sore lesion reached Stage 7, reporting daily for a minimum of 3 days, with the last clinic visit at the time of complete healing or at 14 days, whichever was earlier.

Source ClinicalTrials.gov

Trial

Title
Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for the Treatment of Cold Sores
NCT number
NCT01985321
Phases
PHASE2
Conditions
Recurrent Herpes Labialis
Interventions
ethanol/glycolic acid solution, Placebo/Ethanol
Lead sponsor
Topical Remedy
Results first posted
2015-05-28

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01985321-sae